9 November 2018 - - UK-based Abzena has augmented existing 500 L scale biologics equipment with USD 20m of investment into two new manufacturing suites at 500 L and 2000 L scale in a new GMP facility in San Diego, which will be equipped with Sartorius single use bioreactors, the company said.

Abzena's existing expertise in cell line development is strengthened with a new ambr 15 automated high throughput bioreactor in Cambridge, UK, and existing synthetic chemistry capacity is increased with build out of a fully equipped multifume hood laboratory in Bristol, Pennsylvania.

Dr. Goldman explained that Abzena's antibody Drug Substance manufacturing solution will be built in two new suites housed in the facility recently opened by Abzena in San Diego.

These will contain new Sartorius 500 L and 2000 L single use bioreactors supported by a comprehensive range of scale up and process development equipment.

The service will be further complemented by additional cell line development and chemistry capacity.

Abzena provides the most complete set of solutions in integrated early discovery to mid-phase biotherapeutic and ADC drug development services in the pharmaceutical industry.

The company maintains resources around the world, with facilities in the US and UK. Abzena is partnered with Welsh, Carson, Anderson and Stowe, one of the world's private equity investors.